Introduction
Esophageal cancer is one of the most aggressive and lethal malignancies among gastrointestinal cancer and is the sixth leading cause of cancer death. 1 It has the following two main subtypes: squamous-cell carcinoma and adenocarcinoma. Esophageal squamous cell carcinoma (ESCC) accounts for more than 90% of esophageal cancer cases worldwide. Although advances have been made in the therapy with neoadjuvant chemotherapy or radiochemotherapy, it still remains a major cause of morbidity and mortality in Asia, Africa, and South America. 1 Therefore, new clinical parameters for prognosis and new treatment approaches for adjuvant treatment are needed. A solid tumor is an intricate and dynamic ecosystem comprising tumor cells, immune cells, fibroblasts, blood and lymphoid vessels, nerves, extracellular matrix proteins, endothelial cells, and pericytes. 2 The density and composition of immune cell populations is heterogeneous and is the major factor that determines the fate of cancer, such as the prevention or encouragement of cancer initiation, metastasis and invasion, and angiogenesis. 3 In various human solid cancers, tumor-infiltrating lymphocytes (TILs) are considered to play important roles in orchestrating the immune response to cancer. Among TILs, most CD8 + T cells are cytotoxic T lymphocytes that were generally considered as the main force against cancer. 4 In the vast majority of cancers, the presence, type, and location of CD8 + T cell infiltrates in the tumor mass are associated with longer patient survival. 5 The expression of immunosuppressive proteins (immune checkpoints) on tumor-infiltrating T cells suggests that they help the tumor to evade host immune surveillance. PD-1 and its ligands PD-L1 and PD-L2 are important immune checkpoints.
6-8 PD-1 is an inhibitory co-signal on activated lymphocytes, and PD-1⁄PD-L pathway plays a critical role in inactivation of the endogenous antitumor immune defense. 9 In ESCC, several studies have shown that the expression of the PD-1 on the immune cells, 10 or its ligand PD-L1 and PD-L2 on tumor cells, 11, 12 is associated with a poor clinical outcome. Interestingly, in a recent Phase III trial, favorable responses and survival outcomes were obtained using nivolumab (an anti-PD-1 monoclonal antibody) in advanced squamous cell non-small-cell lung cancer (NSCLC), which is genetically similar to ESCC. 13, 14 Furthermore, a favorable response and durable efficacy of anti-PD-1 monoclonal antibodies for ESCC were established in early clinical trials. 15 Another inhibitory molecule that has received attention recently is T-cell Ig and ITIM domain (TIGIT), which is co-expressed with PD-1 on CD8 + TILs in melanoma, which regulates T-cell function synergistically with PD-1. 16, 17 Immune checkpoint blockade has changed the treatment landscape for a variety of cancers, most prominently melanoma, NSCLC, renal cell carcinoma, and cancers. 13, 18, 19 These marked successes have led to an increased interest in evaluating these agents in several other malignancies including ESCC. It is important to define the combination of immune-based biomarkers that will predict a patients' prognosis and further guide immunotherapeutic approaches.
No published study has systematically examined the coexpression of PD-1, TIGIT, PD-L1, and PD-L2 in ESCC patients before. Thus, this study aimed to investigate the expression and prognostic significance of immune checkpoint receptors and their paired ligands on ESCC in relation to CD8 + T-cell densities. 
Materials and methods

Patient population and tissue samples
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Prognostic significance of immune checkpoints times. Subsequently, the sections were incubated with horseradish peroxidase-conjugated secondary antibody (EnVision Detection Kit; Dako Denmark A/S, Glostrup, Denmark) at room temperature for 30 minutes. After washing three times with PBS, the sections were stained with 3,3′-diaminobenzidine for 1 minute and nuclei were counterstained with hematoxylin. Slides were dehydrated in an ethanol gradient, mounted with neutral gum, and stored at room temperature for later observation.
Evaluation of immunostaining
IHC of PD-L1 and PD-L2 was scored as 0 (no staining), 1+ (weak membranous staining in <10% of the tumor cells), 2+ (weak-to-moderate membranous staining in ≥10% of the tumor cells), and 3+ (strong membranous staining in ≥10% of the tumor cells). Cases that were scored as 2+ or 3+ were considered to be positive for PD-L1 or PD-L2 expression, respectively. Cases that were scored as 0 or 1+ were considered to be negative for PD-L1 or PD-L2 expression, respectively. The density of CD8 + , PD-1 + , and TIGIT + TILs was determined as lymphocytes that infiltrated into cancer nests. The median TILs' count was used as a cutoff to categorize each case into either a high (+) TILs group or a low (-) TILs group. Immune cells were identified by their specific markers (CD8, PD-1, and TIGIT). For each section, a minimum of five areas of a representative field of tumor were assessed with a microscopic field of ×200 (0.933 mm 2 ). The average number of immune cells was calculated as the final density of each section (cells/mm 2 ). All scoring and counting were performed independently by two investigators without knowledge of clinical information.
Statistical analyses
Comparisons among the demographic and pathological features, immune marker densities, and PD-L1 and PD-L2 expressions were evaluated using a Chi-squared test or Fisher's exact test. The difference of TILs density between PD-L1/L2 expression positive and negative was analyzed by the paired t-test. Associations of TILs density between CD8 + , PD-1 + , and TIGIT + were examined by calculating Pearson's correlation coefficient. OS was evaluated using the Kaplan-Meier method, and the differences between survival curves were tested for statistical significance using the log-rank test. The Cox proportional hazards model was used to estimate the independent prognostic factors for OS. All statistical analyses were carried out using SPSS 19.0 (IBM Corporation, Armonk, NY, USA), and a two-sided P-value of <0.05 was considered statistically significant.
Results
Clinical characteristics of patients
A total of 154 (124 males and 30 females) patients were included in the study. The median age was 55 years (range, 37-48 years). The median length of the tumor was 5 cm (range, 2-10 cm). Tumor locations were upper thoracic in 12 patients, middle thoracic in 95 patients, and lower thoracic in 47 patients. The histopathological differentiations were poor in 38 cases, moderate in 73 cases, and well in 43 cases. A total of 108 patients (70.1%) had T3/T4 tumors, and 70 patients (45.5%) had positive lymph nodes. The pathological stages were stage I in eight patients, stage II in 87 patients, stage III in 53 patients, and stage IV in six patients. The estimated 1-, 3-, and 5-year overall survival (OS) rates were 85.1, 61.0, and 51.9%, respectively. The median OS was 41.5 months (range, 1-82 months). Patient characteristics are listed in Table S1 .
The expression pattern of PD-l1 and PD-L2 and the infiltration of PD-1
and CD8
+ Tils in esCC
The PD-1 + , TIGIT + , and CD8 + TILs in cancer nests and the expression of PD-L1 and PD-L2 in tumor tissues were observed by IHC staining. Representative IHC images of PD-L1, PD-L2, PD-1, TIGIT, and CD8 are presented in Figure 1A -E. PD-L1 and PD-L2 were highly expressed in 45.5 and 59.7% of the ESCC samples, respectively (Table  1 and Figure 1A 
Simultaneous expression of immune checkpoints in primary ESCC identifies patients with poor clinical outcome
Kaplan-Meier survival analysis revealed that the patients carrying a high number of PD-1 + TILs (n=73/154, 47.4%) or TIGIT + TILs (n=76/154, 49.4%) tended to exhibit a shorter OS (P=0.044, Figure 3A , and P=0.045, Figure 3B ). Patients with PD-L1-positive tumors (n=83/154, 53.9%) had a shorter OS than those with PD-L1-negative tumors (n=71/154, 46.1%) (P=0.005, Figure 3C ). Patients with PD-L2-positive tumors (n=92/154, 59.7%) displayed a shorter OS compared with those with PD-L2-negative tumor cells (n=62/154, 40.3%) (P=0.002, Figure 3D ).
Multivariate analysis of the patients as grouped was performed with other clinicopathological predictors for survival time using the Cox regression model. The results indicated that PD-1 + TILs, TIGIT + TILs, PD-L1, and PD-L2-positive expressions in cancer were the independent unfavorable prognostic factors in ESCC (Table 3) .
To investigate the impact of immune checkpoint molecules on the prognostic impact of the CD8 + TILs group, we analyzed the protein expression of PD-1 and TIGIT and co-expression in this group of tumors. Kaplan-Meier survival analysis showed that patients carrying a high number of CD8 + TILs (n=64/154, 41.6%) displayed a longer OS than those carrying a low number of CD8 + TILs (CD8 -, n=90/154, 58.4%) (P=0.003, Figure 3E ). However, no significant difference in OS was observed between those with high levels of CD8 Figure  3G ). However, no significant difference in OS was observed between PD-L1-positive/PD-L2-negative or PD-L1-negative/ PD-L2-positive patients and PD-L1-negative/PD-L2-negative patients (P=0.195 and 0.065, Figure 3G ). The median survival time in four groups is 25, 59.5, 42, and 66 months.
To identify the good and poor prognosis of the patients, the combined expression of PD-1, TIGIT in TILs, and PD-L1 and PD-L2 in tumor was analyzed. According to the above prognosis results, we found that patients with PD-1 + / TIGIT + TILs and PD-L1-and/or PD-L2-positive tumor cells (n=34/154, 22.1%) had a markedly shorter OS than patients with PD-1 -/TIGIT -TILs and PD-L1-and PD-L2-negative tumor cells (n=10/154, 6.5%) (P=0.003, Figure 3H ). The median survival time in two groups is 20 and 72.5 months, respectively. In addition, no significant differences were found between PD-1 + or TIGIT + alone and both PD-1
TILs in the patients with PD-L1-and/or PD-L2-positive tumor cells ( Figure 3H ). Similarly, no significant differences 
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Zhao et al were found between PD-1-or TIGIT-alone and both PD-1 -/ TIGIT -TILs in the patients with PD-L1-and PD-L2-negative tumor cells ( Figure 3H ).
Multivariate analysis of the patients as grouped was performed with other clinicopathological predictors for survival time using the Cox regression model. The results indicated that PD-1 + /TIGIT + TILs, PD-L1-positive/PD-L2-positive and combined PD-1 + /TIGIT + TILs, and PD-L1 positive and/or PD-L2 positive in cancer were the independent unfavorable prognostic factors in ESCC (Table 3) .
Discussion
The exploration of immune-based biomarkers involved in tumor microenvironment is becoming a useful strategy to predict patient's outcomes and guide immunotherapy. However, the intricate and dynamic immune microenvironment is heterogeneous in different tumor types. Emerging studies have suggested that tumor may evade host immune response through the expression of immune checkpoints such as PD-1, TIGIT, PD-L1, and PD-L2. A comprehensive detection and assessment of immune checkpoint factors influencing prognosis are important for improving patient management of ESCC. However, there is no previous study on the expression of PD-1, TIGIT, PD-L1, and PD-L2 simultaneously in ESCC tissues. Our results showed that PD-1, TIGIT, PD-L1, and PD-L2 were aberrantly overexpressed in ESCC tissues and these proteins expression alone or together had a significantly poorer prognosis than the negative patients. We also compared and identified the patients' cohort with worst prognosis according the combined expression of PD-1, TIGIT, PD-L1, and PD-L2 in ESCC.
ESCC has been regarded as a proinflammatory neoplasm, where tumor cells produce several cytokines (such as TGF-β, IL-6, IL-8, CCL5, and VEGF) that could lead to the recruitment and activation of polyclonal CD8 + T cells. [20] [21] [22] [23] [24] [25] [26] CD8 + T cell is a crucial component of cell-mediated immunity as it 
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Prognostic significance of immune checkpoints produces interferon-γ (IFN-γ) upon interaction with tumor targets, and CD8 + TILs have been correlated with a favorable outcome in several tumor types. [27] [28] [29] However, recent findings demonstrated that high infiltration of CD8 + T cells correlates with poor survival in renal cell cancer, 30 diffuse large B-cell lymphoma, 31 and Hodgkin lymphoma. 32 It has been reported that IFN-γ can induce PD-L1 expression on tumor cells. 33, 34 In our study, we found that PD-L1-positive tumor had more CD8 + T cells than PD-L1-negative tumor. In addition, a significant positive correlation was found between the densities of PD-1 + or TIGIT + and CD8 + T cells. Survival analysis showed that patients with high CD8 expression had a significantly better clinical outcome than low CD8 expression, but co-expression of PD-1 or TIGIT with CD8 did not significantly decrease the OS in ESCC patients. Therefore, CD8 + T cells may play an important role in suppressing tumor progression in ESCC.
To the best of our knowledge, this is the first report of the poor prognosis associated with high densities of TIGIT + cells in ESCC. In addition, we presented evidence that the expression of PD-1 and TIGIT is highly correlated in ESCC. Patients with high expression of PD-1 or TIGIT have significantly shorter OS than low expression of PD-1 and TIGIT patients, and they have similar survival rate, suggesting that TIGIT may have similar effect with PD-1 in immune inhibition in ESCC. Some studies on mouse models have shown a synergistic effect of the inhibition of both pathways 
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Prognostic significance of immune checkpoints in boosting the antitumor immune response. 17 Thus, our results suggest that cooperation between infiltrating PD-1 + and TIGIT + lymphocytes in tumors might be important in the progression of ESCC and support the rationale of dual blockade of these molecules in ESCC.
Our results found that the density of PD-1 + cells and the tumor expression of PD-L1 in primary ESCC were associated with a poor clinical outcome. Furthermore, we described the prognostic significance of PD-L2. PD-L2 seems to be expressed in a higher proportion of tumors (59.7%) than PD-L1 (53.9%), and PD-L2 expression is associated with a poor clinical outcome. We also found that patients with PD-L1-positive/PD-L2-positive tumor had significantly shorter OS than PD-L1-negative/PD-L2-negative patients, and PD-L1 positive/PD-L2 positive was an independent unfavorable prognostic factor in ESCC. This finding might have clinical relevance because anti-PD-L1 treatment alone seems to have a lower response rate than anti-PD-1. 35, 36 In addition, there are several PD-L1-negative tumors that respond to anti-PD-1 treatment, 35 implying that there are other molecules beside PD-L1 that are involved in the PD-1 inhibition axis of ESCC. A few publications have reported PD-L2 expression in other tumors, including NSCLC, 37 ovarian cancer, and primary mediastinal large B-cell lymphoma, 38, 39 where it has shown a restricted impact on patients' prognosis.
The immunological status in the tumor microenvironment is now well recognized to be a critical determining factor in tumor prevention, development, and progression. Better understanding of the roles of immune cells and molecules in the tumor microenvironment will therefore be essential 
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